RESOURCE LINKS

DRUG ALERTS & UPDATES

EMPLOYEE BENEFIT NEWS

HEALTHCARE NEWS

Advisor Connect:  Your resource center for better outcomes

EmpiRx Health realizes the important role advisors play in optimizing plan performance. Our consultative and collaborative approach empowers benefit advisors with actionable information and tools to educate clients on lowering overall pharmacy costs. Our mission is 100% focused on achieving mutual business growth, superior results, overall satisfaction and lasting partnerships through integrity, trust and respect..

We created an easy to use Advisor Toolkit that provides valuable information to help better manage today’s complex pharmacy benefits and reduce annual drug costs. Use this tool to inform your clients and set a plan of action.

Partner with us:

Phone: 201.746.6902
Email: info@empirxhealth.com

And as we expand our services to our advisors look for these programs coming soon:

  • Loyalty Program
  • Advisory Panel
  • Producer Incentives
  • News and Resources

advisor toolkitExclusively for Advisors

We’re here to help. Click here to get our exclusive Advisor Toolkit, designed to help you create better outcomes for you and your members!

TOOLS & DOWNLOADS

Click here to get our Advisor Connect Toolkit.

NEWS RELEASES

FDA has approved Epclusa – New treatment for Chronic Hepatitis C

On June 28, 2016, FDA approved Gilead’s new drug, Epclusa, to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). For patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.

read more

PCSK9 Inhibitors

What are PCSK9 Inhibitors? The Food and Drug Administration recently approved two products in a new class of cholesterol-lowering drugs known as PCSK9 Inhibitors. This class of drugs reduces the amount of low-density lipoprotein cholesterol (LDL-C), or “bad... read more

Stay informed with our newsletter, publications and more!





I'd like to:


 receive newsletters

Tell us who you are: